PARI has announced that following approval by the FDA, its eRapid nebulizer is now available for delivery of Pulmozyme dornase alfa inhalation solution for the treatment of cystic fibrosis. In Europe, the device, marketed as eFlow Rapid, has been available for use with Pulmozyme for years.
The eRapid nebulizer cuts Pulmozyme delivery time to 2-3 minutes compared to 6-10 minutes for PARI’s LC Plus jet nebulizer. According to PARI USA President Geoff A. Hunziker, the Cystic Fibrosis Foundation encouraged the company to market the system in the US because faster delivery encourages increased compliance.
Genentech’s website for Pulmozyme notes that the eRapid nebulizer is now available but warns that patients might have trouble getting reimbursement for the device: “A new nebulizer, the PARI eRapid has been approved by the FDA for use with Pulmozyme. Gaining access to the eRapid Nebulizer System may involve reimbursement challenges and the eRapid Nebulizer System may not be approved by many payers. Patients who have coverage may encounter significant out-of-pocket costs and patients who do not have coverage may expect to pay full retail price.”
Read the PARI press release.
Read the Genentech Pulmozyme website announcement.
